

Turkish Republic, Ministry of Health 'Türkiye Hudut ve Sahiller Genel Müdürlüğü' to acquire advanced cancer treatment systems from Elekta

Seven hospitals to acquire linear accelerators and sophisticated software for radiation therapy

ISTANBUL, January 16 – Elekta (EKTA-B.ST) has received an order from the Republic of Turkey's Ministry of Health (<u>Directorate General of Health for Border and Coastal Areas</u>) for nine <u>Elekta Synergy</u>[®] linear accelerators (linacs), all including <u>Agility™</u> multileaf collimators for high-resolution beam shaping, as well as <u>Monaco</u>[®] 5.0 treatment planning system and MOSAIQ[®] oncology information system.

Elekta Synergy allows physicians to better visualize tumors while Agility enables precise shaping of the radiation beam around the tumor. Using volumetric modulated arc therapy (VMAT) technology facilitates rapid treatment time, benefitting both the hospitals and patients.

According to the World Health Organization, almost 258 per 100,000 people in Turkey are diagnosed with cancer each year¹. Cancer is the second leading cause of death in Turkey and the most common cancers for men and women are lung and breast, respectively. Elekta Synergy has been clinically proven to be effective in managing both types of cancer, as well as several other indications.²

Ian Alexander, Executive Vice President of Elekta's Region Europe, Africa, Latin America and Middle East, says: "We are delighted to provide the treatment solutions that will allow the Turkish Ministry of Health to offer state-of-the-art cancer care. We're especially pleased that many of the hospitals are new customers to Elekta.

"This is the first major deal procured by our new entity, Elekta Turkey, which was developed through the recent acquisition of Mesi Medikal. We look forward to increased collaboration between our unit and the country's health care sector."

Elekta was awarded the contract based on a public tender where price and performance were the key criteria. The total value of the deal is almost EUR 16 million (approximately USD 18.5 million) and has been booked during Elekta's third quarter 2014/15.

###

For further information, please contact:

Tobias Bülow, Director Financial Communication, Elekta AB Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com

Time zone: CET: Central European Time

Gert van Santen, Group Vice President Corporate Communications, Elekta AB

Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com

Time zone: CET: Central European Time

¹ The International Agency for Research on Cancer (IARC), GLOBOCAN project

² Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates Published online Nov 11, 2014. doi: 10.1186/s13014-014-0243-1

³ Single-Arc Volumetric Modulated Arc Therapy Planning for Left Breast Cancer and Regional Nodes Journal of Radiation Research, Jan 2012



The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on January 16, 2015.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.